International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.

Biotech company Psycheceutical Inc. of Ft. Lauderdale, Fla., was issued two patents by the United States Patent and Trademark Office for what it calls a “precision duplicity” approach to delivering psychedelic drugs to patients.

Nanobiotix is developing a way for the company’s locally injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.

Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.

Researchers are working on a type of vaccine technology using nanoparticles that is less expensive and does not need to be stored at very low temperatures compared to the mRNA technology used by BioNTech-Pfizer and Moderna to develop vaccines against Covid-19.

Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).

Novavax Inc. said South Korea’s SK bioscience would manufacture a component of the U.S. drug developer’s experimental coronavirus vaccine in a bid to boost the clinical-stage biotechnology company’s supply.

With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.

Maryland-based Novavax enrolled and dosed the company’s first patients in a Phase I/II study for a COVID-19 vaccine candidate.

Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.